Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766165 | 0.78 | RAB9A (0.44) | ALDH1A1 | |
| SCHEMBL30068391 | 0.70 | HTR3A (0.32) | — | |
| SCHEMBL10002537 | 0.69 | CDK8 (0.51) | ALDH1A1CCNCCDK8PARP1 | |
| SCHEMBL4051746 | 0.69 | PARP1 (0.36) | CCNCCDK8PARP1 | |
| SCHEMBL26062137 | 0.69 | PARP1 (0.36) | CCNCCDK8PARP1 | |
| SCHEMBL22289900 | 0.64 | NR4A1 (0.36) | RAPGEF4ALDH1A1MAPT | |
| SCHEMBL24331941 | 0.61 | MAPT (0.41) | ALDH1A1MAPT | |
| SCHEMBL22289981 | 0.61 | NOTUM (0.34) | ALDH1A1 | |
| SCHEMBL17868541 | 0.61 | CCNC (0.31) | CCNCCDK8PARP1 | |
| SCHEMBL22289925 | 0.60 | TTR (0.35) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190768-A1 | COMBINATION COMPRISING TRICYCLE COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING HBV | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190768-A1 | COMBINATION COMPRISING TRICYCLE COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING HBV | HAVCR2, TYMP, HLA-B | RAPGEF4 4557/4885ALDH1A1 1688/4885MAPT 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.